Representatives from AbbVie, AstraZeneca, Bristol-Myers Squibb, Janssen Pharmaceuticals, Merck, Pfizer and Sanofi voiced support for drug rebate reform, value-based program creation, and increasing transparency, biologics and generics awareness to lowe…
Author: Healio ophthalmology
Drug companies grilled on pricing in Senate hearing
Representatives from AbbVie, AstraZeneca, Bristol-Myers Squibb, Janssen Pharmaceuticals, Merck, Pfizer and Sanofi voiced support for drug rebate reform, value-based program creation, and increasing transparency, biologics and generics awareness to lowe…
Drug companies support parts of Trump’s plan to lower drug prices
Representatives from AbbVie, AstraZeneca, Bristol-Myers Squibb, Janssen Pharmaceuticals, Merck, Pfizer and Sanofi voiced support for drug rebate reform, value-based program creation, and increasing transparency, biologics and generics awareness to lowe…
Aerie posts fourth quarter, full year financial results
Aerie Pharmaceuticals reported a net loss of $51.5 million, or $1.14 per share, in the fourth quarter of 2018 compared with a net loss of $58.5 million, or $1.60 per share, in 2017’s fourth quarter.The loss includes $14.1 million of gross profit and $6…
Oyster Point raises $93 million in Series B financing
Oyster Point Pharma has completed $93 million in Series B financing, the company announced in a press release.Co-led by Invus Opportunities and Flying L Partners in collaboration with Falcon Vision, as well as existing investors New Enterprise Associat…
VIDEO: Safe alternatives to in-the-bag implantation
ATHENS, Greece — At the European Society of Cataract and Refractive Surgeons Winter Meeting, Michael Amon, MD, speaks about capsular complications in cataract surgery and alternative ways of implanting the IOL.
Hyperopic SMILE shows promise at 1-year follow-up
ATHENS, Greece — Early results of ReLEx small incision lenticule extraction for hyperopia and hyperopic astigmatism seem to indicate that the technique offers promising results.“Despite the common belief that hyperopic SMILE would never be possible, Ze…
Artificial intelligence, machine learning making strides in ophthalmology
WAIKOLOA, Hawaii — Ophthalmologists are using artificial intelligence and machine learning to develop programs to automate diagnoses, improve monitoring and help detect a variety of ophthalmic diseases in patients.“We are being swamped with papers on t…
FDA approves Lotemax SM for postoperative pain, inflammation
The FDA has approved Lotemax SM for the treatment of postoperative inflammation and pain following ocular surgery, Bausch + Lomb announced in a press release.Lotemax SM (loteprednol etabonate ophthalmic gel 0.38%) delivers a submicron particle size tha…
Roche to acquire Spark Therapeutics
Roche will fully acquire Spark Therapeutics in a definitive merger agreement for a price of $114.50 per share.The total equity value of the deal is approximately $4.8 billion, inclusive of approximately $500 million of projected net cash expected at cl…
VIDEO: Intraoperative OCT leads to important discovery in cataract surgery
ATHENS, Greece — The use of intraoperative anterior segment OCT led Boris Malyugin, MD, PhD, to the important discovery that in about half of cases the posterior capsule is detached from the anterior hyaloid. The consequences for surgery are discussed …
VIDEO: More behind the lens than just vitreous
ATHENS, Greece — Behind the lens there is more than just the vitreous, Marie-José Tassignon, MD, PhD, says in this video interview at the European Society of Cataract and Refractive Surgeons Winter Meeting. While performing posterior capsulotomy for im…
VIDEO: Biometry gains precision with AI and intraoperative OCT
ATHENS, Greece — In all fields of medicine, artificial intelligence is greatly transforming the diagnosis and treatment of diseases, leading to improved outcomes. The current applications of artificial intelligence to biometry are explained at the Euro…
Long-term outcomes of CXL, partial topo-guided PRK show efficacy, stability, safety
ATHENS, Greece — Ten-year outcomes of keratoconus management with the Athens protocol, consisting of combined partial topography-guided PRK and cross-linking, show quality and stability, according to the specialist who created this method.“Over the las…
First patient dosed in Ocular Therapeutix wet AMD trial
The first patient has been dosed in a phase 1 clinical trial of OTX-TKI for patients with wet age-related macular degeneration, according to a press release from Ocular Therapeutix.The multicenter, open-label study of OTX-TKI (tyrosine kinase inhibitor…
Kelman Lecture focuses on history, prevention of PCO
ATHENS, Greece — After a long history of partial successes and failed attempts, interesting new developments in IOL technology may be approaching the goal of modulating and controlling posterior capsule opacification, according to David Spalton, MD.In …
Physician burnout rate decreases
The rate of burnout among U.S. physicians dropped in 2017, according to findings published in Mayo Clinic Proceedings.Tait D. Shanafelt, MD, of the department of medicine at Stanford University, and colleagues reviewed responses from 5,445 physicians w…
VIDEO: While volume of myopic SMILE increases, hyperopic SMILE study underway
ATHENS, Greece — Myopic SMILE has become routine in the clinic of Pavel Stodulka, MD, PhD, and half of his refractive procedures are currently SMILE. At the European Society of Cataract and Refractive Surgeons Winter Meeting, he speaks about results, g…
Leiters, Mobius Therapeutics partner to market Mitosol
Leiters and Mobius Therapeutics have entered into a national sales and marketing agreement for the only FDA-approved mitomycin C formulation with an ophthalmic indication, according to a press release.Mitosol (mitomycin for solution 0.2 mg/vial) is ava…
Leiters, Mobius Therapeutics partner to market Mitosol
Leiters and Mobius Therapeutics have entered into a national sales and marketing agreement for the only FDA-approved mitomycin C formulation with an ophthalmic indication, according to a press release.Mitosol (mitomycin for solution 0.2 mg/vial) is ava…